See the DrugPatentWatch profile for tigecycline

Tigecycline is an antibiotic used to treat various bacterial infections, including complicated skin and intra-abdominal infections, and community-acquired bacterial pneumonia [1]. According to the prescribing information, tigecycline has been associated with elevations in liver enzymes, specifically alanine aminotransferase (ALT) and aspartate aminotransferase (AST) [2].

These enzyme elevations are typically asymptomatic and transient, resolving with discontinuation of the drug [2]. However, in rare cases, severe hepatotoxicity has been reported [2]. The mechanism by which tigecycline causes liver enzyme elevation is not well understood, but it is believed to be related to mitochondrial dysfunction [3].

It is important to note that tigecycline-induced liver enzyme elevations are generally mild and asymptomatic, and the drug remains an important antibiotic option for the treatment of serious bacterial infections [1]. Healthcare providers should monitor liver function tests in patients receiving tigecycline and consider discontinuing the drug if significant elevations in liver enzymes occur [2].

In summary, tigecycline has been associated with elevations in liver enzymes, which are typically asymptomatic and transient. The mechanism by which tigecycline causes liver enzyme elevation is not well understood, but it is believed to be related to mitochondrial dysfunction. Healthcare providers should monitor liver function tests in patients receiving tigecycline and consider discontinuing the drug if significant elevations in liver enzymes occur.

Sources:

1. DrugPatentWatch.com. Tigecycline. <https://www.drugpatentwatch.com/drugs/tigecycline>.
2. Tygacil (tigecycline) for injection, for intravenous use. Full Prescribing Information. Pfizer Labs. January 2022. <https://labeling.pfizer.com/showlabeling.aspx?id=958>.
3. Kohler S, Hübner NO, Rübsam-Brodkorb M, et al. Tigecycline-induced hepatotoxicity: a case report and review of the literature. Drug Saf Case Rep. 2018;5:1-5. doi:10.1007/s40800-018-0065-2.